Cytogenetical changes during early stages of development of methotrexate resistance in HeLa cells J. G. DelinassiosM. J. Talieri Articles Pages: 33 - 38
Sequential methotrexate (MTX) and 5-fluorouracil (FU) in human tumor xenografts K. WayssR. HerrmannM. Volm Articles Pages: 27 - 32
Treatment of acute myelogenous leukemia in children G. SchellongU. CreutzigJ. Ritter Articles Pages: 17 - 25
Complete remissions in non small cell lung cancer J. KlasterskyJ. P. SculierP. Mommen Articles Pages: 11 - 15
Production, characteristics and mode of action of hemopoietic growth inhibitors in myeloid leukemias Inge OlssonTor Olofsson Editorial Pages: 1 - 6
The role of monoclonal antibodies in the prevention of graft versus host disease G. JanossyH. G. PrenticeM. J. M. L. Gilmore OriginalPaper Pages: 279 - 284
Chimeric univalent antibodies for treating lymphoid malignancies G. T. StevensonV. M. ColeH. F. Watts OriginalPaper Pages: 275 - 278
The clinical use of monoclonal anti-t-cell antibodies Jean-François BachLucienne Chatenoud OriginalPaper Pages: 269 - 273
Definition of AML susceptibility and classification using monoclonal antibodies Stephanie SeremetisJanet CuttnerRobert Winchester OriginalPaper Pages: 263 - 267
Monoclonal antibodies to human myelomonocyte differentiation antigens in the diagnosis of acute myeloid leukemia Walter KnappOtto MajdicChristian Peschel OriginalPaper Pages: 257 - 262
Dissection of the T-cell circuit with monoclonal antibodies Stuart F. Schlossman OriginalPaper Pages: 247 - 253
Human monoclonal antibodies: Methods of production and some aspects of their application in oncology Lennart Olsson OriginalPaper Pages: 235 - 246
Different ways to modify monoclonal antibodies G. KöhlerB. BaumannD. Zhu OriginalPaper Pages: 227 - 233
Monoclonal immunoglobulins— Development of a concept Jan Waldenström BriefCommunication Pages: 225 - 226
Transfection and cloning of genes for membrane antigens using the FACS Leonard A. HerzenbergCharles HsuPaula Kavathas OriginalPaper Pages: 219 - 224
Plasma kinetics of mitoxantrone in leukemic patients Réginald HulhovenEtienne DumontCarl Harvengt OriginalPaper Pages: 201 - 204
DTIC and CPZ cytotoxicities on established human melanocyte cell lines CH. AubertF. Rouge OriginalPaper Pages: 195 - 199
Plasma pharmacokinetics of adriamycin after intrapleural administration Staffan EksborgAstrid LindforsBjörn J. Cedermark OriginalPaper Pages: 193 - 194
Comparison ofin vitro assays for detecting subpopulations of P388 leukemic cells resistant to AraC Azra RazaKazimierz KuliczkowskiHarvey D. Preisler OriginalPaper Pages: 163 - 168
Differences in surface sialic acid and galactosyl residues of two autologous human melanoma cell lines Max ReynierMichele AuberyChristian Aubert OriginalPaper Pages: 157 - 161
Diagnostic and therapeutic use of monoclonal antibodies to human tumor antigens K. E. HellströmI. HellströmJ. P. Brown OriginalPaper Pages: 143 - 147
Cyclosporine—A model for the testing of bio-immunological reaction modifiers in man R. L. PowlesB. EvansW. Westensee OriginalPaper Pages: 137 - 139
Advanced prostatic adenocarcinoma: Biological aspects and effects of androgen deprivation achieved by castration or agonistic analogues of LHRH G. TolisM. KoutsilierisM. Dufresne OriginalPaper Pages: 129 - 136
Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments Jan G. M. Klijn OriginalPaper Pages: 123 - 128
An oriented phase-II trial ofd-Trp6-LH-RH in patients with prostatic carcinoma G. MathéM. L. VovanA. V. Schally OriginalPaper Pages: 119 - 122
Inhibition of the growth of some hormone dependent tumors byd-Trp6-LH-RH Andrew V. SchallyTommie W. ReddingAna Maria Comaru-Schally OriginalPaper Pages: 109 - 118
Antitumor therapy based on the use of an immune modulator, arginine butyrate and interferon Charles ChanyItalina Cerutti OriginalPaper Pages: 101 - 107
The clinical application of fibroblast interferon—An overview A. Billiau OriginalPaper Pages: 87 - 96
Receptor mediated pathways for interferon action:In vivo implications K. E. MogensenM. -T. BanduP. Eid OriginalPaper Pages: 77 - 85
Generating human monoclonal antibodies A. M. NevilleP. A. W. EdwardsM. J. O'Hare OriginalPaper Pages: 73 - 76
The selection of monoclonal antibodies for tumour localization in patients with colorectal carcinoma Karol SikoraThomas AldersonHoward Smedley OriginalPaper Pages: 63 - 71
Monoclonal antibodies in the treatment of cancer: Preliminary observations and future prospects Robert K. OldhamA. Charles MorganKenneth A. Foon OriginalPaper Pages: 51 - 62
Uptake of adriamycin by human leukemic cells as measured by flow cytometry Harvey D. PreislerAzra Raza OriginalPaper Pages: 43 - 48
Clinical and laboratory findings in untreated patients with Hodgkin’s disease with special reference to age Christina WedelinMagnus BjörkholmHåkan Mellstedt OriginalPaper Pages: 33 - 41
Diagnostic specificity of the monoclonal anti-CALLA antibody VIL-A1 in leukemia and malignant lymphoma W. KnappD. LutzH. Gadner OriginalPaper Pages: 25 - 32
Chemosensitivity tests by a miniclone technique Jan PonténAnders LarsonMargareta Lindström OriginalPaper Pages: 19 - 23
